

## Award Finalist Poster Directory\*

\*Award finalists will man posters during Poster Session I on Monday, April 8, 5:45-7:15 PM, in National BCD

#	Presenter	Title
<i>Finalists: Therapeutic Case Report</i>		
101	Dike, Dozie	High-Dose Vilazodone for the Treatment of Major Depressive Disorder: A Case Report
102	Jones, Jessica	From Mute to Multilingual: Successful Treatment of Benzodiazepine-Refractory Chronic Catatonia with Memantine
<i>Finalists: Innovative Practices</i>		
103	Abelleira, Audrey	Integration of a Psychiatric Clinical Pharmacist Practitioner into a Virtual Long-Term Opioid Therapy Reassessment Clinic
104	Nelson, Leigh Anne	A Novel Advanced Pharmacy Practice Experience (APPE): Scientific Writing with a Focus in Psychiatric Pharmacotherapy
<i>Finalists: Original Research</i>		
105	Kavanagh, Kevin	Do Discharge Medications Prevent Rehospitalization Following Short-Term Crisis Stabilization at a County Psychiatric Hospital?
106	Salwan, Aaron	'Tranq': Perceptions of Xylazine and Harm Reduction Practices Among People Receiving Treatment for Substance Use Disorders
<i>Finalists: Research Trainee</i>		
107	Manley, Kristin	Psychotropic Stewardship: Review of Antipsychotic Polypharmacy at Discharge from a Free-standing Psychiatric Hospital
108	Yang, Michelle	Characterization of Flumazenil Utilization in Electroconvulsive Therapy
<i>Finalists: AAPP Foundation Strategic Goals</i>		
109	Cusimano, Joseph	Development and Validation of an Instrument to Assess Patient Experience of Pharmacist-led Patient Medication Education Groups
110	Tiemann, Allison	Comparison of Pharmacist-Led Outpatient Depression Management to Current Prescriber-Led Depression Management

**Scientific Poster Session I Directory: Students**

#	Presenter	Title
200	Ahmed, Amaal	Pharmacy Students Advancing Mental Health Equity in an Underserved Racial/Ethnic Community
201	Atkins, Gabrielle	Burnout Assessment of Pharmacy and Physician Assistant Program Students at a Historically Black College and University (HBCU)
202	Bullard, Mallory	Assessing the Impact of an Innovate Behavioral Health Urgent Care Clinic
203	Geesey, McKenna	Evaluation of Lithium Utilization at an Inpatient Mental Health Facility to Optimize Patient Outcomes
204	Hallisey, Cameron	Impacts of COVID-19 Events on Clozapine Therapeutics: A Case Report
205	Hanna, Olivia	Zuranolone and Brexanolone: A Review of Novel Treatment Options for Moderate to Severe Postpartum Depression
206	Hayes, Ansley	"Escaping Addiction: Creating a Path to Recovery": A novel escape room game
207	Hilo, Sireen	The Safety and Efficacy of Antidepressants As an Alternative Therapy in the Treatment of ADHD in Pediatric Populations: A Review of the Literature
208	Hreha, Elise	Student Perceptions of Relaxation Before and After Exposure to Relaxation Tools and Techniques
209	Huereca, Karina	Are REM Biomarkers Appropriate for Assessing Clinical Improvement in Major Depressive Disorder?
210	Jones, Colton	Unveiling Stigma in Healthcare: An Exploration of Student Pharmacists', Nurses' and Physicians' Attitudes Towards Mental Illness
211	Krienert, Anna	Cheers to Well-Being: Exploring the Impact of a Peer Support Program on Pharmacy Student Resilience and Happiness
212	Liang, Vivian	Exploring the Potential Efficacy of Medical Cannabis for Major Depressive Disorder: A Systematic Review
213	Maestri, Thomas (Tommy)	Burnout Assessment of Pharmacy Faculty at a Historically Black College and University (HBCU)
214	Miller, Evan	Investigation of the Effects of Medication Adherence on Hospital Admission
215	Miranda Merced, Nilmar	Naloxone Education Program Initiative in FMC, Devens
216	Moreno, Maricela	Trends in the Use of Co - Prescribed Benzodiazepines and Opioids in the United States: 2011 - 2020
217	Musheyev, Ariel	Involvement in Pediatric Psychiatry Pharmacy Intern Shift Improves Self-Efficacy/Comfort
218	Rengan, Rahul	Clozapine-Induced Neutropenia in the Management of Treatment-Resistant Schizophrenia: A Case Report
219	Sepehrara, Soroosh	Correlation Between Higher Screen Time and Decreased Quality of Life in General Adolescents; an Analysis of YRBS Data from CDC
220	Swanson, Ingrid	Evaluating the Impact of Photovoice on Self-Stigma Levels Among Individuals with Substance Use Concerns
221	Waggoner, Hallie	Evaluation of Bupropion Renal Dose Adjustment at an Inpatient Mental Health Facility to Optimize Patient Outcomes
222	Wang, Zhijie	Examining the Correlation Between Follow-Up After Opioid Overdose and Clinical Outcomes at Los Angeles General Medical Center
223	Ward, Taylor	Long Acting Injectable Antipsychotic Use and Discontinuation Rates in Pediatric Patients Using Medicaid Claims Data

**Scientific Poster Session I Directory: Pharmacists and Other Health Care Professionals**

#	Presenter	Title
300	Ballani, Kanika	Treatment patterns and outcomes from OASIS: Observational Study of Long-Acting Injectables in Schizophrenia
301	Bishop, Jeffrey	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants
302	Boggs, Doug	Efficacy, Tolerability, and Safety of AXS-05, a Novel Oral Antidepressant: Data From 3 Clinical Trials
303	Boggs, Doug	Impact of AXS-05, an Oral NMDA Receptor Antagonist and Sigma-1 Receptor Agonist, on Anhedonic Symptoms in Major Depressive Disorder
304	Borovicka, Mary	Antipsychotic-Induced Muscle-Specific Tyrosine Kinase (MuSK) Antibody Positive Myasthenia Gravis
305	Borovicka, Mary	Impact of Pharmacist Administration of Long-Acting Injectable Antipsychotics in Community Pharmacies
306	Crismon, M. Lynn	Long-term Follow-up of Implementation of Psychotropic Medication Utilization Parameters for Children and Adolescents in Texas Foster Care
307	Cutler, Andrew	Healthcare Resource Utilization Following 6 Months of Treatment with Olanzapine/Samidorphan: Real-World Assessment of Patients with Schizophrenia or Bipolar I Disorder
308	Darling, Diane	Anticholinergics are Not Appropriate Treatments for Tardive Dyskinesia: Insights from an Expert Panel of Psychiatry and Neurology Healthcare Professionals
309	Douglass, Amber	Exploring the Harm Reduction Paradigm: The Role of Board-Certified Psychiatric Pharmacists
310	Earnest, Jami	Pharmacokinetics of Viloxazine ER (Viloxazine Extended-Release Capsules) in Breastmilk of Healthy Lactating Women
311	Eggert, Robyn	Eliminating Drug Cost as Barrier to Medication Access
312	English, Clayton	Mental and Behavioral Health Supports and Services Provided by Pharmacists in Washington State
313	Fahmy, Monica	Evaluation of Workload and Burnout Among Psychiatric Pharmacists in the United States
314	Flynn, Courtney	Opioid Treatment Programs, Healthcare Resource Utilization, and Healthcare Costs among patients initiating treatment with Buprenorphine Extended-Release
315	Formella, Andrea	Viloxazine ER Administered with Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Phase IV Safety Trial
316	Gaiazov, Sabrina	Emergency Room (ER) Visits Among Opioid Use Disorder (OUD) Patients
317	Greer, Daniel	Comparing Effectiveness Between Different Antidepressants in Preventing Psychiatric Rehospitalization
318	Haghpars, Parna	Treatment Resistant Priapism in a 61-Year-Old Male After Combined Use of Trazodone, Quetiapine, and Fluoxetine
319	Harris, Suzanne	Analysis of Experiential Education Absence Policies for Mental Health Criteria
320	Hedgepeth Kennedy, M. Lindsey	ATLAS - Addiction Treatment: Linking Access & Services Mobile Clinic Reducing Stigma-related Barriers in Rural NC
321	Hokett, Sonja	Real-World Clinical Experience of Dexmedetomidine Sublingual Film for Agitation in Adults with Schizophrenia or Bipolar Disorder
322	Hokett, Sonja	Treatment and Economic Challenges when Treating Patients with Agitation Associated with Schizophrenia or Bipolar Disorder in the Emergency Department (ED)
323	Kando, Judith	Efficacy of KarXT (Xanomeline and Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials

**Scientific Poster Session I Directory: Pharmacists and Other Health Care Professionals**

#	Presenter	Title
324	Kando , Judith	Safety and Tolerability of KarXT (Xanomeline and Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
325	Kando, Judith	Long-Term Metabolic Outcomes associated with KarXT (Xanomeline and Trospium): Interim Results from Pooled, Long-Term Safety Studies EMERGENT-4 and EMERGENT-5
326	Karas, Andrew	A Pharmacist-Driven Therapeutic Drug Monitoring Program for Mood Stabilizers
327	Lang, Shelby	Acute Suicidal Ideation and Thoughts of Self-harm with Valbenazine
328	Leung, Jonathan	Alice in Wonderland Syndrome Associated with Topiramate
329	Loo, Bradford	Efficacy of Lumateperone in Pooled Short-Term Late-Phase Clinical Trials for Treatment of Major Depressive Episodes Associated with Bipolar II Disorder
330	Loo, Bradford	Lumateperone Treatment for Major Depressive Episodes with Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder
331	Lorenz, Raymond	The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients with Major Depressive Disorder in a Randomized Controlled Trial
332	Maheshwari, Priya	Impact of Combinatorial Pharmacogenomic Testing on Hospitalization Rates in a Real-World Dataset of Patients with Major Depressive Disorder
333	Maister, Ashley	Utilization of Lidocaine/Epinephrine to Minimize Injection Site Pain for Patients Receiving Subcutaneous Extended-Release Buprenorphine
334	Malik, Hirah	Database Analysis for the Concomitant Use of an Immediate-Release Stimulant with an Extended-Release Stimulant for the Treatment of ADHD
335	Mandarino, Michael	Impact of Clinical Pharmacist Intervention on a Neuropsychiatry and Behavioral Neurology Consult Service at a Free-standing Psychiatric Hospital
336	Markowitz, John	Investigating the Inhibitory Effects of Cannabis Smoke Condensate on Cytochrome P450 in the Human Lung
337	Maroney, Megan	Analysis of Anxiety, Stress, and Depression Trends in Pharmacy Students Pre- vs Post- Pandemic
338	Maroney, Megan	The Role of Social Media on Dissemination of Information Regarding Antidepressants
339	McGuire, Michael	Pharmacist Run Pharmacotherapy Clinic Utilizing Behavioral Health Intervention Billing
340	Ngo, Priscilla	Establishment of Behavioral Health Pharmacy Service Line at a Rural, Critical Access Indian Health Service Hospital System
341	Ogunmekan, Amenaghawon	Baseline demographics and clinical characteristics from OASIS: Observational Study of Long-Acting Injectables in Schizophrenia
342	Palmer, Emma	A Retrospective Review of Changes in Rate of Psychosis - Related Inpatient Psychiatric Admissions and Recent Stimulant Prescriptions at a Non-Profit Psychiatric Facility
343	Parkman, Thomas	Formation of a Working Alliance and Efficacy of a Digital Therapeutic to Treat Experiential Negative Symptoms of Schizophrenia
344	Parmentier, Brittany	Managing Prescription Assistance Program Discontinuation at a Certified Community Behavioral Health Clinic
345	Price, Paul	A Student-led, Free Clinic Provides Access to Naloxone in an Underserved Population
346	Price, Paul	Evaluating the Impact of Pre- and Post-Exams on Psychiatry Pharmacy Student Rotations: A Comprehensive Analysis
347	Rarrick, Christine	Impact of Paroxetine 2D6 Inhibition in a Patient Transitioned From Oral Risperidone to Paliperidone Palmitate: A Case Report
348	Rola, Alexandra	Evaluating Outcomes of Psychotropic Drug Safety Initiative (PDSI) Management System for Management of Stimulant Use at a Medical Center

**Scientific Poster Session I Directory: Pharmacists and Other Health Care Professionals**

#	Presenter	Title
349	Romer, Brittney	Evaluation of Medication Assisted Treatment (MAT) Program Enrollment and Treatment Retention, pre and post Drug Addiction Treatment Act (DATA) Waiver Elimination
350	Sanchez, Tara	Patients Requiring Early Administration of Maintenance Long-Acting Injectable Antipsychotic Dose
351	Silvia, Richard	Pharmacist-Provided Education on Antipsychotic Monitoring Parameters after the COVID-19 Pandemic
352	Soubolsky, Amy	An Outpatient Pharmacist Consultation Service to Help Address a Psychiatry Waitlist Crisis: Protocol for Implementation and Program Evaluation
353	Strand, Lauren	Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen
354	Stutzman, Danielle	Role of Board-Certified Psychiatric Pharmacists in Child and Adolescent Psychiatry
355	Sundling, Kimberly	A Managed Healthcare Integrated Care Program for Severe Mental Illness (SMI)
356	Temelie, Andreea	Antipsychotic-induced Tics in Autism Spectrum Disorder
357	Teter, Christian	Impact of Viloxazine Extended-Release Capsules on Self-Rated Executive Function in a Long-Term, Phase 3, Open-Label Extension Trial of Adult ADHD
358	Trotter, Kara	Switching Patients with Schizophrenia to TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA), From Risperidone Microspheres (R064766): An Exploration of Population Pharmacokinetic (PopPK)-Based Strategies
359	Vadiei, Nina	Extent, patterns and predictors of contraception use among women of child-bearing age prescribed valproic acid in the United States
360	Vento-Correa, Maria	Exploring the Impact of Oral Antidepressant Class Selection on Esketamine-Treated Patients with Treatment-Resistant Depression
361	Williams, Andrew	Comparison of High-Dose Olanzapine and Standard-Dose Olanzapine in Adult Patients at a County Psychiatric Hospital: A Retrospective Study
362	Wong, Kara	Evaluating the Impact of an Automated Phone Outreach Program on Naloxone Prescribing to Veterans At-Risk for Opioid Overdose

**Scientific Poster Session 2 Directory: Residents and Fellows**

#	Presenter	Title
400	Albiar, Olivia	Impact of Antipsychotic Therapeutic Drug Monitoring (TDM) in a Mental Health Intensive Case Management Team
401	Arizpe, Anthony	Re-Evaluation of Stimulant Prescribing Patterns of Veterans Affairs Outpatient Mental Health Providers: A Five-Year Follow Up Study
402	Beach, Kayla	Implementation of a Pharmacist-Driven Long-Acting Injectable Antipsychotic Stewardship Program at VA Sierra Nevada Health Care System
403	Benkart, Caitlin	Treatment Engagement of Patients Initiated on Extended-Release Injectable Naltrexone for Alcohol Use Disorder in the Inpatient Setting
404	Bernardo, Charmaine	Implementation of a Standardized Buprenorphine/Naloxone Induction Protocol on an Inpatient Psychiatry Unit
405	Bindseil, Isabelle	Evaluation of Aripiprazole in the Treatment of Food Avoidant Behaviors among Adolescents with Anorexia Nervosa
406	Bye, Katie	Assessment of Clozapine Therapeutic Drug Monitoring

**Scientific Poster Session 2 Directory: Residents and Fellows**

#	Presenter	Title
407	Callahan, Katherine	Comparison of Rehospitalization Outcomes in the Veteran Population Administered Long-acting Injectable Naltrexone Versus Oral Naltrexone for Alcohol Use Disorder Before Discharge
408	Campbell, Amanda	Prevalence of Asymptomatic Bacteriuria in Psychiatric Patients at a County Safety Net Hospital
409	Canto, Samantha	Clozapine, Caffeine, and Smoking: A Correlational Study and Initiation of Pharmacist-Led Interventions to Improve Clinical Outcomes
410	Castro, Angelica	Impact of Medication Reviews by Pharmacists in Veterans Flagged High Risk for Suicide
411	Cervenak, Markella	Retrospective Review of Patients' Receiving Long-Acting Injectables on Inpatient Behavioral Units to Assess the Impact of Pharmacist Led Administration in Outpatient and Retail Settings
412	Chen, Kevin	Standardizing the Inpatient Medication Reconciliation Process for Long-Acting Injectable Antipsychotics
413	Clergeau, Vanessa	Comparing Buprenorphine Prescription Patterns for Opioid Use Disorder (OUD) Before and After the Drug Addiction Treatment Act (DATA)-waiver Removal at a Hospital Healthcare System
414	Cliatt, Hayley	Implementation of a Pharmacist Driven Long-Acting Injectable Antipsychotic Transitions of Care Service
415	Cohen, Alexandra	Influence of Patient Gender on Antipsychotic Selection in an Acute Inpatient Setting
416	Dean, Meagan	Implementation and Impact of Psychotropic Stewardship at a Large Academic Medical Center
417	Dike, Amara	Enhancing Buprenorphine Access and Identifying Treatment Barriers in Veterans with Opioid Use Disorder
418	Dorve-Lewis, Paige	Evaluation of Intentional Overdose Trends among Youth in Pennsylvania Before and During the COVID-19 Pandemic
419	Dorve-Lewis, Paige	Overdose Prevention Strategies in High-Risk Youth Populations; Impact of Pharmacist-Driven Intervention and Interprofessional Collaboration
420	Dues, Alyssa	Assessing Acute Agitation Management at a Federal Health Care Center
421	Easey, Taylor	Implementation of a Pharmacist-led Mental Health Transitions of Care Clinic for Patients Discharged from a Residential Rehabilitation Treatment Program
422	Gamcsik, Sarah	Impact of the Stimulant Shortage on Prescribing Patterns in a Child and Adolescent Psychiatry Outpatient Clinic
423	Giakoumas, Konstandina	The Effect of Mental Health Clinical Pharmacy Specialist Intervention on Cardiovascular Safety and Urine Drug Screen Monitoring for Patients Prescribed Stimulants at the Cincinnati Veterans Affairs Medical Center
424	Greear, Derek	Examining the Interventions of an Interdisciplinary Overdose Review Team (ORT) at a Rural Veterans Affairs Medical Center
425	Gregory, Michael	Impact of Pharmacist-Led Intervention in Veteran Patients with Positive Alcohol Use Disorder Identification Test on Access to Care and Clinical Metrics
426	Gregory, Michael	Pharmacist-Led Intervention To Improve Adherence of Antidepressants and Address Potential Barriers Using Population Health Dashboard at a Rural Veterans Hospital
427	Haiby, Lincoln	Behavioral Health Agitation Protocol Impact on As Needed Medication Use
428	Harrison, Makenzie	Effect of Clozapine for Depressive Symptoms in Black Patients with Schizophrenia or Schizoaffective Disorders
429	Hartman, Caroline	Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression Relapse
430	Hean, Andrew	Evaluation of Pharmacy Resident Burnout and Career Satisfaction Based on Residency Staffing Model

**Scientific Poster Session 2 Directory: Residents and Fellows**

#	Presenter	Title
431	Howington, Jessica	The Impact of Long-Acting Injectable Antipsychotic Therapies Versus Oral Antipsychotic Therapies on Adherence and Clinical Outcomes
432	Ironbar, Catherine	Establishing Monitoring Standards for Medication Therapy for Adults with Attention Deficit Hyperactivity Disorder (ADHD)
433	Isler, Zachae	Clinical Pharmacist Efforts to Increase Access to Buprenorphine in Veteran Population
434	Johnson, Roland	Assessment of Long-Acting Injectable Antipsychotic Use and Hospital Readmissions After a Pilot Formulary Expansion
435	Kajtazovic, Selma	Protocol Deviations of Inpatient Medication Order Adjustments Associated with Electroconvulsive Therapy
436	Kastberg, Kaitlyn	Mental Healthcare Utilization Among Transgender Individuals in a Community Psychiatric Hospital
437	Khan, Hejab	Comparison of Treatment Outcomes in the Veteran Population Administered Aripiprazole Long-acting Injectable Versus Paliperidone Palmitate Long-acting Injectable for Bipolar Disorder in the Inpatient Setting
438	Koebel, Katelyn	Assessing the Applicability of Drug-Related Concentration (DRC) Factors for Antipsychotics in Forensic Psychiatric Patients
439	Kovalic, Leah	A Comparative Analysis of Metabolic Monitoring for Second Generation Antipsychotics (SGAs) in an Outpatient Psychiatry Clinic for Patients with and without Pharmacist Co-Management
440	Laboy Collazo, Valeria	Lithium and Antipsychotics in Post-Partum Psychosis: Utilization of Pro re Nata Medications on an Inpatient Psychiatric Perinatal Unit
441	Lamb, Maxwell	Impact of Pharmacist-led Ambulatory Alcohol Detoxification
442	Lawrence, Maddox	Providing Targeted Outreach for Pharmacogenomic Testing to Actionable Veterans with Post Traumatic Stress Disorder (PTSD)
443	Levin, Daniel	Evaluating the Use of a Pharmacist Led Initiative in Reducing Anticholinergic Burden at a State Psychiatric Hospital
444	Little, Allison	Medication Use Evaluation of Micro-Induction of Buprenorphine-Naloxone in a Stepped Care Model
445	Lu, Kelvin	Evaluation of Behavioral Health Pharmacy Advocates (BHPA), a Training Program for Pharmacy Personnel
446	Ly, Yennhi	Expanding Buprenorphine Access in a Primary Care Setting at an Ambulatory Outpatient Clinic
447	Marks, Katherine	Utility of a Clinical Pharmacist Practitioner in the Deprescribing of Z-hypnotics in Older Adults
448	Martin, Antoinette	Hit Me with Your Best Shot: Implementation and Evaluation of Clinical Pharmacist Impact within a Long-Acting Injectable Antipsychotic Clinic at a Veterans Affairs Medical Center
449	Matalaka, Marian	Increase Access to Naloxone for Veterans Enrolled in Home Based Primary Care
450	Matthews, Hunter	Evaluation of the Impact of Concomitant Valproic Acid and Lorazepam Administration on Sedation
451	Meeks, Matie	Buprenorphine Micro-induction and Bridge Dosing Outcomes
452	Mohebbi, Sheila	Pharmacists' Attitudes Towards Psychedelics and their use in Therapy
453	Mott, Alexandra	Transition of Veterans with Mental Health Disorders from Mental Health Clinic to Primary Care Clinic
454	Neeman, Jake	Psychotropic Prescribing Patterns Among Forensic Psychiatric Inpatients with and without Borderline Personality Disorder

**Scientific Poster Session 2 Directory: Residents and Fellows**

#	Presenter	Title
455	Nguyen, Julie	Impact of Pharmacist Intervention on Appropriate Prescribed Stimulant Monitoring Among Veterans
456	Noteboom, Alix	Alcohol Use Relapse Rates for Patients with Liver Transplants in Early vs Standard Transplant Timeline
457	Parizher, Jacqueline	Investigating Presence of Race Based Prescribing Differences in Hospitalized Patients Starting Buprenorphine using Transdermal Patch Micro-induction Method
458	Patel, Sahil	Impact of Pharmacist-driven Intervention to Improve Long-acting Injectable Paliperidone Palmitate Administration and Ordering
459	Phung, Stephanie	Evaluation of Treatment for Mania in Veterans with Bipolar I Disorder
460	Popp, Carissa	Does Patient Attitude Toward Psychiatric Drug Therapy Impact Adherence to Their Medications?
461	Quesinberry, Erika	Kratom: A Veteran's Ally or Adversary?
462	Rashid, Leyla	Impact of MH PGY2 Pharmacy Resident Outreach to Veterans with Potentially Untreated Opioid Use Disorder Recently Discharged from the Emergency Department
463	Rodriguez, Derek	Duloxetine for Treatment Resistant Depression in Older Adults
464	Rofe, Austin	Pharmacist Managed Anxiety and Depression Treatment at a Federally Qualified Health Center
465	Roth, Winter	Changes in Attitudes and Behaviors Associated with Buprenorphine Best Practices Dissemination
466	Salinas, Viana	Improving the Utilization of Long-Acting Injectable Antipsychotics in Eligible Veterans at a Veterans Affairs Outpatient Health Care System
467	Salsman, Madeline	Impact of Pharmacist Led Contingency Management in Patients with Substance Use Disorders
468	Schoch, Tricia	Establishing a Pharmacist-Run, Outpatient Long-Acting Injectable Antipsychotic Clinic in a Safety Net Hospital
469	Sibley, Cassandra	Relapse Rates Among Veterans on Maintenance Doses of Oral Buprenorphine/Naloxone versus Subcutaneous Extended-Release Buprenorphine for Opioid Use Disorder
470	Smith, Amanda	Evaluation of Current Valproic Acid Monitoring Practices in Inpatient Psychiatric Settings
471	Sun, Christina	Long-Acting Injectable Antipsychotic Use in Pediatric and Adolescent Patients with Psychiatric Disorders
472	Sweeney, Caroline	Integration of a Clinical Pharmacist into Geriatric Psychiatry Treatment Team within a Veterans Affairs Healthcare System
473	Tenorio, Liliana	Exploring the Need for Weight Loss Interventions in Clozapine Patients at a Veterans Affairs Healthcare System
474	Timmons, Nolan	Quality Improvement for Pediatric Opioid, Benzodiazepine, and Alcohol Detoxification Treatment through Development and Implementation of a Standardized System Wide Protocol
475	Towers, Margaret	Comparing the Cognitive Effect of Vortioxetine versus Other Selective Serotonin Receptor Inhibitors
476	Verdin, Mariah	Effectiveness of Tetrabenazine for the Treatment of Antipsychotic-induced Tardive Dyskinesia
477	Wade, Alexa	Comparison of Kloxxado® and Narcan® Usage Following Updates to Computerized Patient Record System
478	Wadlow, Allison	Utilizing Therapeutic Drug Monitoring to Optimize Dosing of Antipsychotics on Inpatient Behavioral Health Units



**Scientific Poster Session 2 Directory: Residents and Fellows**

#	Presenter	Title
479	Wallace, Leah	Implementation of mMINDS Monitoring for Alcohol Withdrawal at an Academic Psychiatric Facility
480	Weller, Nathan	Assessing Documentation of Clozapine Trials in Patients Prescribed Antipsychotic Polypharmacy Regimens at Discharge
481	White, Kelley	Prescribing Patterns of Valproic Acid and Derivatives in Nursing Home Residents with Dementia
482	White, Olivia	Evaluating the Occurrence of Mania-Related Hospitalizations in Patients with Bipolar Disorder or Schizoaffective Disorder Receiving Antidepressant Therapy
483	White, Samara	Assessment of Psychiatric Patients' Actual QTc Intervals vs. Predicted QTc Prolongation Risk
484	Williams, Kayla	The Effect of Montelukast on Suicidal Ideation in the Veteran Population
485	Wojtowicz, Jeremiah	Evaluation of EKG Monitoring for Citalopram and Escitalopram
486	Yates, Madison	Improving Veteran No-Show Rates at an Outpatient Mental Health Clinic Through Implementation of Measurement-Based Care Reminders
487	Zhang, Lusi	Establishing a Database to Examine the Real-World Impact of Psychiatric Pharmacogenomic Testing in a Large Health System
488	Zhang, Lusi	Relevance of Psychiatry-Focused Pharmacogenomic Test Results to Non-Psychiatric Medications Treatment in Pediatric and Adult Patients

## 2024 Scientific Poster Sessions and Awards Abstract Reviewers

Audrey Abelleira, PharmD, BCPP, BCPS	Taylor Harlow, PharmD, BCPP	Kristen Pellingra, PharmD, BCPP, BCPS
Jade L. Abudia, PharmD, BCPP	Claire Herbst, PharmD, BCPP, BCPS	Dillon C. Perryman, PharmD, BCCP
Elayne D. Ansara, PharmD, BCPP, BCPS	Dorothy Nicole. Holzum, PharmD, BCPP, BCPS	Jennifer Preinitz, PharmD, BCPS, BCPP
Bailey Bass, PharmD, BCPS	Justine B. Jeter, PharmD, BCPP	Paul L. Price, PharmD, BCPP
Jennifer Bean, PharmD, BCPP, BCPS	Arianna Johnson, PharmD	Charles Reynolds, PharmD, BCPP
Allison Beatty, PharmD, BCCP	Jessica F. Jones, PharmD, BCPP	Jill Reynoldson, PharmD, BCPP
Jami L. Butz, PharmD, BCGP, BCPP	Erin D. Knox, PharmD, BCPP	Samantha L. Schulte, PharmD, BCPP
Vicky C. Chan, PharmD, BCPS	Shelly L. Lettmann, PharmD, BCPP	Shaina E. Schwartz, PharmD, BCPP
Heng Chang, PharmD, BCPS	Jonathan G. Leung, PharmD, BCPP, BCPS	Rajkumar J. Sevak, PhD, RPh
Hannah Christensen, PharmD, BCPP	Gary M. Levin, PharmD, BCPP, FCCP	Alexandra Sklansky, PharmD, BCPP
Marissa Cullen, PharmD, BCPP	Jonathan F. Lister, PharmD, BCPP	Karrie Squires, PharmD, BCPP
Joseph M. Cusimano, PharmD, BCPP	Ashley Maister, PharmD, BCPP	Viktoriya Titova, PharmD, BCPP
Nicolle Dambly, PharmD	Erin R. Mathis, PharmD, BCPP	Anamarie Tomaich, PharmD
Jeremy Daniel, PharmD, BCPP, BCPS	Erin McAllister, PharmD, BCPP	Minh-Thi Ton, PharmD
Amber R. Douglass, PharmD, BCPS, BCPP	Talia M. Miles, PharmD, BCPP, BCPS	Rebecca Tourtellotte, PharmD, BCPP, BCPS
Anna Dugovich, PharmD	Eileen Mintz, PharmD, BCPP	Cindy K. Trac, BCPS
Traci M. Dutton, PharmD, BCPP, BCPS	Sandra Mitchell, PharmD, BCPP	Kristen M. Ward, PharmD
Abimbola Farinde, PharmD	Sarah Norman, PharmD, BCPS, BCPP, BCGP	Kristina Ward, PharmD, BCPP
Kristy Fitzgerald, PharmD, MBA	Megan OConnell, PharmD, BCPP	Carolanne C. Wartman, PharmD, BCPS, BCCP
Jenna Gilbert, PharmD, BCPP	Ijeoma E. Onyema, PharmD, BCPP	Kristin Waters, PharmD, BCPP, BCPS
Bridgette Gleisner, BCPP	Anne Ottney, PharmD, BCPS	Sujin Lee. Weinstein, PharmD, BCPP
Emily N. Gray, PharmD, BCPP	Isaac Pan, PharmD, BCPP, MS	Andrew M. Williams, PharmD, BCPP
Melissa Mooers. Gross, PharmD, BCPP, BCPS, BCGP	Kalee M. Parkins, PharmD, BCPP	Shannon L. Zandy, PharmD, PhD
Abigail Hampton, PharmD, BCPP	Krina Patel, PharmD, BCPP	